Concepedia

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

John B. Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E. Schmidt, Eduard Montanya, Jason Brett, Marcin Zychma, Lawrence Blonde

The Lancet · 2009 · 1.5K citations · 25 references

DOI

Concepts

References

25

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

David M. Nathan, John B. Buse, Mayer B. Davidson et al. · Diabetes Care · 2008 · 3.8K citations · Full text

, , +17

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Ralph A. DeFronzo, Robert E. Ratner, Jenny Han et al. · Diabetes Care · 2005 · 1.6K citations

, , +11

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

John B. Buse, Robert R. Henry, Jenny Han et al. · Diabetes Care · 2004 · 1.3K citations · Full text

, , +14

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

David M. Kendall, Matthew C. Riddle, Julio Rosenstock et al. · Diabetes Care · 2005 · 1.2K citations · Full text

, , +17

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Michael A. Nauck, Anders Frid, Kjeld Hermansen et al. · Diabetes Care · 2008 · 1.1K citations · Full text

, , +17